Literature DB >> 10408717

Prognostic factors for survival in multiple sclerosis.

Z M Lević1, I Dujmović, T Pekmezović, M Jarebinski, J Marinković, N Stojsavljević, J Drulović.   

Abstract

In a hospital-based study of 119 patients with definite multiple sclerosis, demographic and clinical factors were analysed with respect to their validity in assessing the long-term prognosis. Over a mean follow-up of 21.7 years, the following factors negatively influenced the prognosis by the univariate analysis: male sex, age at onset over 25, pyramidal involvement or spasticity at onset, > or =3 functional systems affected at onset or after 5 years, incomplete first remission, length of the first remission < or =1 year, >5 attacks in the first 10 years, secondary or primary-progressive disease, time to reach secondary progression over 5 years and time to reach EDSS 6 over 7 years. The multivariate model showed that in patients with relapsing-remitting disease, 5 years after onset, pyramidal involvement at onset and shorter time to reach EDSS 6 predicted poor outcome, while after 10 years, higher age at onset and incomplete first remission indicated poor prognosis. Ten years after onset, the predictors of poor outcome in the secondary-progressive group were shorter time to reach EDSS 6 or secondary progression and higher EDSS, while in the primary-progressive group those variables were spasticity or higher number of functional systems affected at onset, and higher EDSS after 5 and 10 years.

Entities:  

Mesh:

Year:  1999        PMID: 10408717     DOI: 10.1177/135245859900500306

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

Review 1.  Gender disparities in ocular inflammatory disorders.

Authors:  Hatice Nida Sen; Janet Davis; Didar Ucar; Austin Fox; Chi Chao Chan; Debra A Goldstein
Journal:  Curr Eye Res       Date:  2014-07-02       Impact factor: 2.424

Review 2.  Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.

Authors:  Vera Pravica; Dusan Popadic; Emina Savic; Milos Markovic; Jelena Drulovic; Marija Mostarica-Stojkovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

4.  Clinical characteristics of patients with late-onset multiple sclerosis.

Authors:  Bernhard Kis; Bastian Rumberg; Peter Berlit
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

Review 5.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran.

Authors:  Seyed Mohammad Masood Hojjati; Seyyed Ali Hojjati; Mobina Baes; Ali Bijani
Journal:  Caspian J Intern Med       Date:  2014

7.  Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Authors:  Emmanuelle Leray; Sandra Vukusic; Marc Debouverie; Michel Clanet; Bruno Brochet; Jérôme de Sèze; Hélène Zéphir; Gilles Defer; Christine Lebrun-Frenay; Thibault Moreau; Pierre Clavelou; Jean Pelletier; Eric Berger; Philippe Cabre; Jean-Philippe Camdessanché; Shoshannah Kalson-Ray; Christian Confavreux; Gilles Edan
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

8.  Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29.

Authors:  Joel Raffel; Alison Wallace; Djordje Gveric; Richard Reynolds; Tim Friede; Richard Nicholas
Journal:  PLoS Med       Date:  2017-07-10       Impact factor: 11.069

9.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.